Alphavirus replicon vector systems

Details Alphavirus replicon vector systems Alphavirus replicon vector systems

2008-09-16

2008-09-16

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S325000, C435S091420

Reexamination Certificate

active

11376901

ABSTRACT:
The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.

REFERENCES:
patent: 4650764 (1987-03-01), Temin
patent: 4708871 (1987-11-01), Geysen
patent: 5091309 (1992-02-01), Schlesinger
patent: 5185440 (1993-02-01), Davis
patent: 5217879 (1993-06-01), Huang
patent: 5505947 (1996-04-01), Johnston
patent: 5521082 (1996-05-01), Lewis et al.
patent: 5639650 (1997-06-01), Johnston
patent: 5643576 (1997-07-01), Johnston
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5726022 (1998-03-01), Burmer
patent: 5739026 (1998-04-01), Garoff
patent: 5766602 (1998-06-01), Xiong
patent: 5789245 (1998-08-01), Dubensky
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5811407 (1998-09-01), Johnston
patent: 5814482 (1998-09-01), Dubensky
patent: 5827658 (1998-10-01), Liang et al.
patent: 5831016 (1998-11-01), Wang et al.
patent: 5843723 (1998-12-01), Dubensky
patent: 5853719 (1998-12-01), Nair et al.
patent: 5958738 (1999-09-01), Lindemann et al.
patent: 5989553 (1999-11-01), Johnston et al.
patent: 6008035 (1999-12-01), Johnston
patent: 6015686 (2000-01-01), Dubensky
patent: 6015694 (2000-01-01), Dubensky
patent: 6146874 (2000-11-01), Zolotukhin
patent: 6156558 (2000-12-01), Johnston
patent: 6190666 (2001-02-01), Garoff
patent: 6194191 (2001-02-01), Zhang et al.
patent: 6197502 (2001-03-01), Renner et al.
patent: 6224879 (2001-05-01), Sjoberg
patent: 6242259 (2001-06-01), Polo
patent: 6261570 (2001-07-01), Parker
patent: 6267967 (2001-07-01), Johnston et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342372 (2002-01-01), Dubensky
patent: 6376236 (2002-04-01), Dubensky
patent: 6391632 (2002-05-01), Dubensky
patent: 6426196 (2002-07-01), Dubensky et al.
patent: 6485958 (2002-11-01), Blanche et al.
patent: 6495143 (2002-12-01), Lee et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6531135 (2003-03-01), Johnston et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6583121 (2003-06-01), Johnston et al.
patent: 6767699 (2004-07-01), Polo et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: 6783939 (2004-08-01), Olmsted et al.
patent: 6844188 (2005-01-01), MacDonald et al.
patent: 7045335 (2006-05-01), Smith et al.
patent: 7235235 (2007-06-01), Johnston et al.
patent: 2001/0016199 (2001-08-01), Johnston et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0034521 (2002-03-01), Lee et al.
patent: 2002/0102273 (2002-08-01), Grieve et al.
patent: 2002/0141975 (2002-10-01), Olmsted et al.
patent: 2002/0164582 (2002-11-01), Hart et al.
patent: 2003/0021766 (2003-01-01), Vadjy et al.
patent: 2003/0091591 (2003-05-01), Xiong et al.
patent: 2003/0096397 (2003-05-01), Schlesinger et al.
patent: 2003/0119182 (2003-06-01), Smith et al.
patent: 2003/0120060 (2003-06-01), Gonczol et al.
patent: 2003/0148262 (2003-08-01), Polo et al.
patent: 2003/0152590 (2003-08-01), Hevey et al.
patent: 2003/0232036 (2003-12-01), Johnston et al.
patent: 2003/0232324 (2003-12-01), Polo et al.
patent: 2004/0009183 (2004-01-01), Lee et al.
patent: 2004/0009945 (2004-01-01), Lee et al.
patent: 2004/0029279 (2004-02-01), Kovacs et al.
patent: 2004/0030117 (2004-02-01), Johnston et al.
patent: 2004/0121466 (2004-06-01), Johnston et al.
patent: 2004/0146859 (2004-07-01), Hart et al.
patent: 2004/0166573 (2004-08-01), Smith et al.
patent: 2004/0208848 (2004-10-01), Smith et al.
patent: 2005/0031592 (2005-02-01), Doolan et al.
patent: 2005/0054107 (2005-03-01), Chulay et al.
patent: 2005/0118251 (2005-06-01), Nagata et al.
patent: WO 02/10578 (1992-06-01), None
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 99/07834 (1999-02-01), None
patent: WO 99/08706 (1999-02-01), None
patent: WO 99/51263 (1999-10-01), None
patent: WO 00/39302 (2000-07-01), None
patent: WO 00/39318 (2000-07-01), None
patent: WO 00/61772 (2000-10-01), None
patent: WO 01/16343 (2001-03-01), None
patent: WO 02/003917 (2002-01-01), None
patent: WO 02/04493 (2002-01-01), None
patent: WO 02/20721 (2002-03-01), None
patent: WO 03/023026 (2003-03-01), None
patent: WO 03/083065 (2003-10-01), None
patent: WO 04/055166 (2004-07-01), None
patent: WO 04/055167 (2004-07-01), None
patent: WO 04/085660 (2004-10-01), None
patent: WO 05/007689 (2005-01-01), None
Lemm et al., Assembly of Functional Sindbis Virus RNA Replication Complexes: Requirement for Coexpression of P123 and P34,.1993, Journal of Virology, vol. 67, No. 4, pp. 1905-1915.
Documents from the Opposition filed by Chiron Corporation in the Australian Patent Office against the grant of Australian Patent No. 727036 (Australian Application Serial No. 59256/96) including (i) Notice of Opposition filed by Chiron Corporation dated Feb 28, 2001; (ii) Statement of Grounds of Opposition and Particulars Relating to Each Ground filed by Chiron Corporation dated May 28, 2001; (iii) Evidence-in-Support filed by Chiron Corporation including Statutory Declaration of Nicholas James Finnie dated May 28, 2002 with Exhibits NJF-1 to NJF-13; Statutory Declaration of John Polo dated Aug. 27, 2002 with Exhibits JP-1 to JP-10; and Statutory Declaration of Alexander A. Khromykh dated Oct. 14, 2002 with Exhibits AK-1 to AK-2; (iv) Submission by Chiron Corporation to Commissioner of Patents, Australia dated May 11, 2006 advising that the opposition against the grant of Australian Patent No. 727036 is withdrawn; and (v) Communication issued by IP Australia acknowledging withdrawal of opposition by Chiron Corporation.
Baric et al. “Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons”,Journal of Virology76(6):3023-3030 (2002).
Davis et al.“Alphavirus Replicon Particles as Candidate HIV Vaccines”IUBMB Life53:209-211 (2002).
Eiben et al. “Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice”Cancer Research62:5792-5799 (2002).
Eralp et al. “Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed Against HER 2
eu in a Murine Mammary Carcinoma Model”Breast Cancer Research6:R275-R283 (2004).
Gidwitz et al. “Differences in virion stability among Sindbis virus pathogenesis mutants”Virus Research10:225-240 (1988).
Johnston et al. “Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus”Virology162:437-443 (1988).
Johnston et al. “Studies of Alphavirus Virulence Using Full-Length Clones of Sindbis and Venezuelan Equine Encephalitis Viruses” M.A. Brinton et al. (eds),New Aspects of Positive Strand RNA Viruses, pp. 334-339 ASM Press, (1990).
Kaufman et al. “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus”Nucleic Acids Research19(16):4485-4490 (1991).
Khromyck “Replicon-based vectors of positive strand RNA viruses” Current Opinion in Molecular Therapeutics 2(5):555-569 (2000).
Lee et al. “Candidate Vaccine Against Botulinum Neurotoxin Serotype A Derived from a Venezuelan Equine Encephalitis Virus Vector System”Infection and Immunity69(9):5709-5715 (2001).
Lee et al. “Immune Protection Against Staphylococcal Enterotoxin-Induced Toxic Shock by Vaccination with a Venezuelan Equine Encephalitis Virus Replicon”Journal of Infectious Diseas

Affiliated with

Also associated with

Rating

Alphavirus replicon vector systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alphavirus replicon vector systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alphavirus replicon vector systems will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3939087